Effect of Prevnar 13 on Ear Infections in Children

NCT01199016

Last updated date
Study Location
Penfield Pediatrics
Penfield, New York, 14526, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Otitis Media
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-30 months
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject has received full (3-dose) infant series of Prevnar 13

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Prior vaccination with any 7vPnC.


- Prior vaccination with 23-valent pneumococcal polysaccharide vaccine (23vPS).


- Any major illness/condition that, in the investigator's judgment, will substantially
increase the risk associated with the subject's participation in the study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Otitis MediaEffect of Prevnar 13 on Ear Infections in Children
NCT01199016
  1. Penfield, New York
  2. Rochester, New York
  3. Rochester, New York
  4. Rochester, New York
  5. Rochester, New York
  6. Rochester, New York
  7. Rochester, New York
ALL GENDERS
6 Months+
years
MULTIPLE SITES
Otitis MediaStudy Evaluating Microbiological Analysis of Spontaneous Draining Acute Otitis Media
NCT00768534
  1. Tegernsee, Bavarian
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Otitis MediaZmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media
NCT00360100
  1. Bardstown, Kentucky
  2. Springfield, Kentucky
  3. Cordoba,
  4. Santiago, RM
  5. Independencia, Santiago
  6. Providencia, Santiago
  7. San Jose,
  8. Santo Domingo, DN
  9. Ciudad Guatemala,
  10. Guatemala,
  11. Ciudad de Panama,
ALL GENDERS
3 Months+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Effect of Prevnar 13 on Ear Infections in Children
Official Title "a Phase 4, Postmarketing Study Evaluating The Impact Of Prevnar 13 (Trademark)(13-valent Pneumococcal Conjugate Vaccine; 13vpnc) In Reducing Acute Otitis Media And Nasopharyngeal Colonization Caused By Streptococcus Pneumoniae In Healthy Children
Brief Summary Prevnar (7 valent pneumococcal conjugate vaccine [7vPnC]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar. It is expected that the effectiveness of Prevnar 13 against ear infections in children will be similar to that observed following Prevnar. Pfizer has committed to conduct a postmarketing study of the impact of Prevnar 13 in reducing ear infections among children.
Detailed Description Infants who have completed the Prevnar 13 infant vaccination series who provide consent and fit the study inclusion criteria to participate in the study will be recruited.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
Middle Ear Fluid for microbiologic analysis Nose and throat swab for microbiologic analysis
Sampling Method Non-Probability Sample
Study Population Healthy children aged approximately 6 to 36 months of age.
Condition Otitis Media
Intervention
  • Procedure: Tympanocentesis
    To be performed as needed on children presenting with acute otitis media
  • Procedure: Nose/throat swab
    To be performed at every study visit
  • Biological: Observational
    Observational Study Only
Study Groups/Cohorts 1
Interventions:
  • Procedure: Tympanocentesis
  • Procedure: Nose/throat swab
  • Biological: Observational
Publications * Pichichero M, Kaur R, Scott DA, Gruber WC, Trammel J, Almudevar A, Center KJ. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study. Lancet Child Adolesc Health. 2018 Aug;2(8):561-568. doi: 10.1016/S2352-4642(18)30168-8. Epub 2018 Jun 19.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: April 26, 2016)
239
Original Estimated Enrollment
 (submitted: September 9, 2010)
360
Actual Study Completion Date January 2016
Actual Primary Completion Date January 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Subject has received full (3-dose) infant series of Prevnar 13

Exclusion Criteria:

  • Prior vaccination with any 7vPnC.
  • Prior vaccination with 23-valent pneumococcal polysaccharide vaccine (23vPS).
  • Any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in the study.
Sex/Gender
Sexes Eligible for Study:All
Ages 6 Months to 30 Months   (Child)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT01199016
Other Study ID Numbers 6096A1-4010
B1851018 ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date December 2016